Compare JOE & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOE | PBLS |
|---|---|---|
| Founded | 1936 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.4B |
| IPO Year | 2002 | 2026 |
| Metric | JOE | PBLS |
|---|---|---|
| Price | $61.23 | $30.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 311.3K | ★ 544.5K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 56.69 | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | ★ $513,246,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $255.29 | ★ N/A |
| Revenue Growth | ★ 27.44 | N/A |
| 52 Week Low | $46.37 | $25.56 |
| 52 Week High | $73.54 | $33.65 |
| Indicator | JOE | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 39.98 | 62.34 |
| Support Level | $58.93 | $26.68 |
| Resistance Level | $62.29 | $30.19 |
| Average True Range (ATR) | 1.89 | 2.45 |
| MACD | -0.39 | 0.29 |
| Stochastic Oscillator | 27.72 | 57.11 |
The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.